Clinical studies have found that high doses of an experimental drug developed by Biogen, called aducanumab, has been proven to reduce toxic brain plaques and slow the onset of memory loss. To date, pharmaceutical companies have spent billions of dollars on drugs to cure Alzheimer’s without any success.
One reason why aducanumab has been successful is the fact that it attacks toxic forms of the amyloid protein which is thought to damage brain cells. It also enhances existing immune cells in the brain which attack these toxins. However, there have been associated side effects including fluid to the brain and in rare cases bleeding.
The study is still in the beginning phases. So far only 165 patients in early stages of Alzheimer’s have been a part of the trial. Biogen recently started another study with 2,700 patients. Results will not be concluded for several years to come.
Devoted specifically to the Retired population, we hold Alzheimer’s and the fight for a cure close to our hearts. Join our team on November 12th as we Walk to End Alzheimer’s.